In a nutshell This study reported the long-term effectiveness and safety outcomes of apalutamide (Erleada) in combination with androgen deprivation therapy (ADT) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). The data showed that this combination improved survival, delayed castration resistance, and maintained the...
Read More
In a nutshell This study compared the survival and safety outcomes of pembrolizumab (Keytruda; PEM) plus enzalutamide (Xtandi; ENZ) combination versus pembrolizumab alone in patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that PEM plus ENZ combination was associated with increased survival...
Read More
In a nutshell This study compared the outcomes of robotic-assisted radical prostatectomy (RARP) with standard laparoscopic radical prostatectomy (LRP) for the treatment of patients with localized prostate cancer. The study found that the RARP approach was associated with better outcomes compared to LRP. Some background Localized prostate cancer (PCa)...
Read More
In a nutshell This study looked at the use of focal cryotherapy (FC) for the treatment of low- to intermediate-risk prostate cancer (PC). The authors found that the use of FC was safe and increased time to further therapy with similar survival compared to active surveillance (AS). Some background PC is one of the most common forms of...
Read More
In a nutshell This study reviewed the effectiveness and safety of lutetium-177 [177Lu]-prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that PRLT was associated with good outcomes and manageable side effects. Some...
Read More
In a nutshell The study compared patient-reported outcomes (PRO) in patients receiving continuous androgen deprivation therapy (CADT) vs intermittent androgen deprivation therapy (IADT) for locally advanced prostate cancer (PCa). The study reported that PROs were significantly improved with IADT. Some background ADT is a hormonal therapy...
Read More
In a nutshell This study investigated the effectiveness and safety of re-irradiation in the treatment of patients with relapsed prostate cancer (PCa). The data showed that the use of re-irradiation in these patients was associated with good outcomes and low toxicity. Some background Radiotherapy (RT) is an effective treatment for localized prostate...
Read More
In a nutshell This study compared the outcomes of Retzius-sparing (RS) robotic-assisted laparoscopic prostatectomy (RALP) with standard RALP (sRALP) for the treatment of patients with localized prostate cancer (PCa). The study found that the RS-RALP approach may be associated with better urinary outcomes compared to sRALP. Some background...
Read More
In a nutshell The study investigated the effectiveness of combining sipuleucel-T (Provenge) with radium-223 (Xofigo) therapy in men with castration-resistant prostate cancer (CRPC) that has spread to the bones. The key finding was that the combination therapy improved the survival rates of these patients. Some background Prostate cancer often...
Read More
In a nutshell This trial is aiming to assess the effectiveness of nivolumab (Opdivo) with or without ipilimumab (Yervoy) in treating metastatic prostate cancer according to the percentage of CD8 cells patients have. The main outcomes that are to be measured are the clinical benefit rate and the percentage of CD8 cells on biopsy during...
Read More
In a nutshell This study aimed to evaluate the effectiveness of physical exercise in patients with prostate cancer. The study concluded that physical exercise is associated with reduction of tiredness, and improving functional capacity and quality of life in these patients. Some background Prostate cancer (PCa) is the second most common form of...
Read More
In a nutshell This study investigated the outcomes and effectiveness of administering additional (adjuvant) androgen deprivation therapy (A-ADT) for long-term after radiotherapy (RT) in high-risk or very high-risk locally advanced prostate cancer (LAPC). The study found that the addition of A-ADT longer than 1 year after RT showed good treatment outcomes...
Read More
